Table 4 Ongoing trials with immunotherapy in HER2 + breast cancer patients, early setting
From: Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Drug | Phase | Setting | Status | Type of intervention | Mechanism of action | |
|---|---|---|---|---|---|---|
NCT03595592 [118] | Atezolizumab+ Pertuzumab+ Trastuzumab+ Chemotherapy | III | Early | Recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT03726879 [119] | Atezolizumab+ Pertuzumab+ Trastuzumab+ Chemotherapy | III | Early | Recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT01570036 [120] | Nelipepimut+ Trastuzumab | II | Early‡ | Completed | Vaccine | Peptide-based vaccine (E75) |
NCT01479244 [121] | Nelipepimut+ Sagramostim | II | Early‡ | Completed | Vaccine | Peptide-based vaccine (E75) |
NCT02605915 [108] | Atezolizumab+ Pertuzumab + Trastuzumab + or Atezolizumab+TDM-1 | IB | Early and metastatic | Active, not recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT03321981 [122] | MCLA-128 | II | Early | Recruiting | HER2-block enhancer | ADCC stimulation against HER2/HER3 receptors |
NCT03747120 [123] | Pembrolizumab+ Paclitaxel+ Pertuzumab + Trastuzumab | II | Early | Recruiting | Immune check point inhibitor | Anti PD-1 |
NCT01355393 [124] | NA | I/II | Early | Active, notrecruiting | Vaccine | Peptide vaccine |
NCT00436254 [115] | NA | I | Early and Metastatic | Active, not recruiting | Vaccine | pNGVL3-hICD vaccine |
NCT03742986 [125] | Nivolumab + docetaxel+ Pertuzumab+ Trastuzumab | II | Early | Not yet recruiting | Immune checkpoint inhibitor | Anti PD-1 |
NCT03387553 [126] | NA | I | Early | Recruiting | Vaccine | DC Vaccine |
NCT03630809 [127] | NA | II | Early | Recruiting | Vaccine | DC vaccine |
NCT03620201 [128] | NA | I | Early | Recruiting | Immune checkpoint inhibitor | Anti PD-L1/TGF-Beta TRAP. |
NCT03820141 [129] | Durvalumab + Trastuzumab+ Pertuzumab | II* | Early | Not yet recruiting | Immune checkpoint inhibitor | Anti PD-L1 |